WilmerHale Advises Underwriters in Follow-on Public Offering of CinCor Pharma, Inc.

WilmerHale Advises Underwriters in Follow-on Public Offering of CinCor Pharma, Inc.

Client News
WilmerHale represented the underwriters in the follow-on public offering of 6,025,000 shares of common stock and 2,600,000 pre-funded warrants to purchase common stock of CinCor Pharma, Inc., a biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat (CIN-107), for the treatment of hypertension and other cardio-renal diseases. The shares of common stock were issued at a public offering price of $30.00 per share. The pre-funded warrants had a public offering price of $29.99 per pre-funded warrant. The gross proceeds to CinCor were $225 million, before deducting underwriting discounts, commissions and offering expenses. The offering priced on August 10, 2022 and closed on August 15, 2022.

The WilmerHale team consisted of Lisa Firenze, Glenn Pollner, Ryan Brewer, Molly Nelson, and Frank Wang, with assistance from Bruce Manheim and Colleen Superko.